Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy
- PMID: 25562645
- DOI: 10.1146/annurev-pharmtox-010611-134654
Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy
Abstract
Designed ankyrin repeat proteins (DARPins) can recognize targets with specificities and affinities that equal or surpass those of antibodies, but because of their robustness and extreme stability, they allow a multitude of more advanced formats and applications. This review highlights recent advances in DARPin design, illustrates their properties, and gives some examples of their use. In research, they have been established as intracellular, real-time sensors of protein conformations and as crystallization chaperones. For future therapies, DARPins have been developed by advanced, structure-based protein engineering to selectively induce apoptosis in tumors by uncoupling surface receptors from their signaling cascades. They have also been used successfully for retargeting viruses. In ongoing clinical trials, DARPins have shown good safety and efficacy in macular degeneration diseases. These developments all ultimately exploit the high stability, solubility, and aggregation resistance of these molecules, permitting a wide range of conjugates and fusions to be produced and purified.
Keywords: directed evolution; protein engineering; protein scaffold; sensors; tumor targeting; virus retargeting.
Similar articles
-
Advances in the Application of Designed Ankyrin Repeat Proteins (DARPins) as Research Tools and Protein Therapeutics.Methods Mol Biol. 2018;1798:307-327. doi: 10.1007/978-1-4939-7893-9_23. Methods Mol Biol. 2018. PMID: 29868969 Review.
-
Designed ankyrin repeat proteins (DARPins) from research to therapy.Methods Enzymol. 2012;503:101-34. doi: 10.1016/B978-0-12-396962-0.00005-7. Methods Enzymol. 2012. PMID: 22230567
-
DARPin-Based Crystallization Chaperones Exploit Molecular Geometry as a Screening Dimension in Protein Crystallography.J Mol Biol. 2016 Apr 24;428(8):1574-88. doi: 10.1016/j.jmb.2016.03.002. Epub 2016 Mar 11. J Mol Biol. 2016. PMID: 26975886
-
From DARPins to LoopDARPins: novel LoopDARPin design allows the selection of low picomolar binders in a single round of ribosome display.J Mol Biol. 2014 Feb 6;426(3):691-721. doi: 10.1016/j.jmb.2013.10.026. J Mol Biol. 2014. PMID: 24513107
-
DARPins: a true alternative to antibodies.Curr Opin Drug Discov Devel. 2007 Mar;10(2):153-9. Curr Opin Drug Discov Devel. 2007. PMID: 17436550 Review.
Cited by
-
DARPin-fused T cell engager for adenovirus-mediated cancer therapy.Mol Ther Oncol. 2024 May 29;32(3):200821. doi: 10.1016/j.omton.2024.200821. eCollection 2024 Sep 19. Mol Ther Oncol. 2024. PMID: 39021370 Free PMC article.
-
Design of a symmetry-broken tetrahedral protein cage by a method of internal steric occlusion.bioRxiv [Preprint]. 2023 Nov 9:2023.11.08.566319. doi: 10.1101/2023.11.08.566319. bioRxiv. 2023. Update in: Protein Sci. 2024 Apr;33(4):e4973. doi: 10.1002/pro.4973 PMID: 37986890 Free PMC article. Updated. Preprint.
-
A simple strategy for retargeting lentiviral vectors to desired cell types via a disulfide-bond-forming protein-peptide pair.Sci Rep. 2018 Jul 20;8(1):10990. doi: 10.1038/s41598-018-29253-5. Sci Rep. 2018. PMID: 30030466 Free PMC article.
-
Cellular and Structural Studies of Eukaryotic Cells by Cryo-Electron Tomography.Cells. 2019 Jan 16;8(1):57. doi: 10.3390/cells8010057. Cells. 2019. PMID: 30654455 Free PMC article. Review.
-
Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration.J Ocul Pharmacol Ther. 2018 Dec;34(10):700-709. doi: 10.1089/jop.2018.0062. Epub 2018 Nov 9. J Ocul Pharmacol Ther. 2018. PMID: 30412448 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
